MedTrace Logo

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

NCT06582771 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-03-25

No results posted yet for this study

Summary

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)

Conditions

  • Non Small Lung Cancer

Interventions

DRUG

Sotorasib

Sotorasib 960 mg (8 pills) daily

Sponsors & Collaborators

Principal Investigators

  • Gregory Riely, MD, PhD · Memorial Sloan Kettering Cancer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-30
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582771 on ClinicalTrials.gov